CRISPR Therapeutics CRSP Accrued Expenses
Accrued Expenses at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherLiabilitiesCurrent.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's accrued expenses.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's accrued expenses?
- CRISPR Therapeutics (CRSP) reported accrued expenses of $13.11M in Q1 2026.
- What is the long-term trend for CRISPR Therapeutics's accrued expenses?
- Over 5 years (2020 to 2025), CRISPR Therapeutics's accrued expenses has grown at a 12.7% compound annual growth rate (CAGR), from $7.21M to $13.11M.
- What does accrued expenses mean?
- Expenses incurred but not yet paid or invoiced — interest accruals, tax accruals, warranty reserves, and other timing differences.